**Consortium Goals and Purpose**

**VISION**
To understand and cure histiocytic diseases.

**MISSION**
To cure all patients with histiocytic diseases and optimize outcomes through innovative and collaborative research.

**GOALS**
- To develop a network for the advancement of clinical, translational, and basic research in histiocytic diseases.
- To advance therapeutic, etiological and mechanistic research through the implementation of high impact clinical trials and organized collection of well annotated clinical data and biology specimens.
- To define the pathogenesis of histiocytic diseases and develop risk-stratification strategies with tissue samples from patients treated on NACHO trials

**RESEARCH**
NACHO can rapidly design and implement pilot translational research and clinical research initiatives. While many other initiatives will be developed and executed in the future, the collaboration was launched with the implementation of high-impact clinical trials complimented by companion biology studies to facilitate prospective collection of biological samples.

**NACHO Membership**

Learn more about NACHO at www.NACHO-Consortium.org

*With support from Histiocytosis Association
*With support from Leukemia & Lymphoma Society

---

**NORTH AMERICAN CONSORTIUM FOR HISTIOCYTOSIS (NACHO)**

The North American Consortium for Histiocytosis (NACHO) is the first multi-institutional consortium in North America with a solid scientific agenda and the research infrastructure necessary for the development and effective implementation of clinical and translational studies and biological research for histiocytic diseases.

Under the direction of Consortium PI Dr. Carlos Rodriguez-Galindo, NACHO’s Operations Center is located at St. Jude Children’s Research Hospital. Dr. Carl Allen, Consortium Co-PI, leads the Biology Center at Texas Children’s Hospital.